Diagnosis and treatment of adenovirus infection in immunocompromised patients.
In immunocompromised patients, human adenovirus (HAdV) infections can cause life-threatening multiorgan disease. This review summarizes the incidence and risk factors of invasive human adenovirus infections in immunocompromised patients as well as the recently developed standards for diagnostic methods and strategies according to the predominant risk factors in adults and children. Recommendations for preemptive and therapeutic treatment strategies and the outcome in different risk groups are presented. Novel therapeutic approaches including CMX001, a new orally bioavailable lipid conjugate of cidofovir and the transfer of adenovirus-specific donor T cells in the context of allogeneic stem cell transplantation are discussed.
St Anna Children's Hospital, Stem cell transplantation, Medical University of Vienna, Vienna, Austria.
Susanne
S
Matthes-Martin
Heidrun
H
Boztug
Thomas
T
Lion
D000258:Adenovirus Infections, Human / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*; D000260:Adenoviruses, Human / Q000276:immunology*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D063065:Organophosphonates / Q000627:therapeutic use*; D012307:Risk Factors; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
D000998:Antiviral Agents; D063065:Organophosphonates; C525733:brincidofovir; D003596:Cytosine